The success of blinatumomab (Blincyto) in the treatment of patients with B-cell acute lymphoblastic leukemia (ALL) is a notable advance in the management of this disease (G?kbuget et al., 2018; Kantarjian et al., 2017; Martinelli et al., 2021; Topp et al., 2015). Expanding the clinical application of bispecific antibodies across other lymphoid malignancies is a next logical step. Recent approvals including polatuzumab vedotin (Polivy), tafasitamab (Monjuvi), loncastuximab tesirine (Zynlonta), and selinexor (Xpovio) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLCBL) do not clearly reflect the effort to establish a bispecific antibody in this space (Caimi et al., 2021; Kalakonda et al., 2020; Salles et al., 2020; Sehn et al., 2020). However, despite false starts, the design of easily administered, well-tolerated, and highly efficacious bispecific antibodies continues to occupy a significant space in the development of innovative treatments for DLBCL. Understanding the key features of bispecific antibodies and thereby the implications of structure on both efficacy and tolerability can assist in efforts to successfully incorporate this therapeutic strategy among previously treated patients with DLBCL.
展开▼
